Price History
Apr 8, 2026 — Jul 6, 2026Investment Snapshot
- P/B of 11.40 — trading above book value
- Piotroski F-Score 3/9 — signs of financial weakness
- Loss-making — negative ROE of -211.6%
Nasus Pharma Ltd. Ordinary Shares (NSRX) is a Healthcare company operating in Drug Manufacturers - General, listed on the AMEX , with a market capitalisation of $32 million . Key value metrics: P/B ratio 11.40, Piotroski F-Score 3 out of 9 .
Value Score
Key Metrics
Nasus Pharma Ltd. Ordinary Shares — Fundamental Analysis Summary
On financial health, NSRX shows a weak Piotroski F-Score of 3/9, a signal of deteriorating financial health, and negative return on equity of -211.6% (sector average: -20.6%).
StockPik's composite Value Score for NSRX is 33/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
NSRX shows earnings declining at 282%.